• Product name

    Anti-KCNE2 antibody
  • Description

    Rabbit polyclonal to KCNE2
  • Host species

  • Tested applications

    Suitable for: WB, IHC-Pmore details
  • Species reactivity

    Reacts with: Mouse, Human
  • Immunogen

    Synthetic peptide corresponding to Human KCNE2 aa 1-100 conjugated to keyhole limpet haemocyanin.
    (Peptide available as ab86641)

  • Positive control

    • This antibody gave a positive signal in mouse pancreas tissue lysate.



Our Abpromise guarantee covers the use of ab69376 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB Use at an assay dependent concentration. Detects a band of approximately 17 kDa (predicted molecular weight: 14 kDa).
IHC-P Use a concentration of 5 µg/ml. Perform heat mediated antigen retrieval before commencing with IHC staining protocol.


  • Function

    Ancillary protein that assembles as a beta subunit with a voltage-gated potassium channel complex of pore-forming alpha subunits. Modulates the gating kinetics and enhances stability of the channel complex. Associated with KCNH2/HERG is proposed to form the rapidly activating component of the delayed rectifying potassium current in heart (IKr). May associate with KCNQ2 and/or KCNQ3 and modulate the native M-type current. May associate with KCNQ1/KVLTQ1 and elicit a voltage-independent current. May associate with HCN1 and HCN2 and increase potassium current.
  • Tissue specificity

    Highly expressed in brain, heart, skeletal muscle, pancreas, placenta, kidney, colon and thymus. A small but significant expression is found in liver, ovary, testis, prostate, small intestine and leukocytes. Very low expression, nearly undetectable, in lung and spleen.
  • Involvement in disease

    Defects in KCNE2 are the cause of long QT syndrome type 6 (LQT6) [MIM:613693]. Long QT syndromes are heart disorders characterized by a prolonged QT interval on the ECG and polymorphic ventricular arrhythmias. They cause syncope and sudden death in response to exercise or emotional stress. KCNE2 mutants form channels that open slowly and close rapidly, thereby diminishing potassium currents.
    Defects in KCNE2 are the cause of atrial fibrillation familial type 4 (ATFB4) [MIM:611493]. Atrial fibrillation is a common disorder of cardiac rhythm that is hereditary in a small subgroup of patients. It is characterized by disorganized atrial electrical activity and ineffective atrial contraction promoting blood stasis in the atria and reduces ventricular filling. It can result in palpitations, syncope, thromboembolic stroke, and congestive heart failure.
  • Sequence similarities

    Belongs to the potassium channel KCNE family.
  • Cellular localization

  • Information by UniProt
  • Database links

  • Alternative names

    • ATFB4 antibody
    • cardiac voltage gated potassium channel accessory subunit 2 antibody
    • Kcne2 antibody
    • KCNE2_HUMAN antibody
    • LQT5 antibody
    • LQT6 antibody
    • minimum potassium ion channel related peptide 1 antibody
    • Minimum potassium ion channel-related peptide 1 antibody
    • minK related peptide 1 antibody
    • MinK-related peptide 1 antibody
    • MIRP1 antibody
    • Potassium channel subunit beta MiRP1 antibody
    • potassium channel subunit, MiRP1 antibody
    • potassium voltage gated channel subfamily E member 2 antibody
    • potassium voltage gated channel, Isk related family, member 2 antibody
    • Potassium voltage-gated channel subfamily E member 2 antibody
    • voltage-gated K+ channel subunit MIRP1 antibody
    see all


  • Anti-KCNE2 antibody (ab69376) at 1 µg/ml + Pancreas (Mouse) Tissue Lysate at 10 µg

    Goat polyclonal to Rabbit IgG - H&L - Pre-Adsorbed (HRP) at 1/3000 dilution

    Developed using the ECL technique.

    Predicted band size: 14 kDa
    Observed band size: 17 kDa
    why is the actual band size different from the predicted?

    KCNE2 contains a number of potential glycosylation sites (SwissProt) which may explain its migration at a higher molecular weight than predicted. Furthermore, this reaction is also observed in other commercially available antibodies to KCNE2.
  • IHC image of KCNE2 staining in human normal kidney formalin fixed paraffin embedded tissue section, performed on a Leica BondTM system using the standard protocol F. The section was pre-treated using heat mediated antigen retrieval with sodium citrate buffer (pH6, epitope retrieval solution 1) for 20 mins. The section was then incubated with ab69376, 5µg/ml, for 15 mins at room temperature and detected using an HRP conjugated compact polymer system. DAB was used as the chromogen. The section was then counterstained with haematoxylin and mounted with DPX.


This product has been referenced in:

  • Wei H  et al. miR-584-5p regulates hepatocellular carcinoma cell migration and invasion through targeting KCNE2. Mol Genet Genomic Med 7:e702 (2019). Read more (PubMed: 31044566) »
See 1 Publication for this product

Customer reviews and Q&As

1-2 of 2 Abreviews or Q&A


Indeed there are 2 glycosylation sites for this protein and if you prevent glycosylation of this protein then it should decrease the apparent size of the protein. However, glycosyl groups are small and therefore probably are not the cause for this higher molecular weight observed and even if they were removed, you probably wouldn't have a band at the correct molecular weight of 14 kDa.

Read More


If this band is indeed due to a dimerisation then I would sugest boiling the samples in SDS-PAge for 10 minutes to try and disrupt the formation of this multimer. Have you already tried this?
Is just one band being detected at 34 kDa? We have a blocking peptide, ab86641 against this antibody which could help determine non-specific binding.

Read More

For licensing inquiries, please contact partnerships@abcam.com

Sign up